Qiagen (QGEN) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.65
- Estimate
- $0.63
- Surprise
- +3.6%
- Score at report (before → after)
- 5.3 → 5.1/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Qiagen (QGEN) beat the $0.63 estimate with adjusted EPS of $0.65 — a clear 3.6% upside surprise. TrendMatrix's engine moved from Hold (5.3/10) to Sell at 5.1/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates QGEN Sell at 5.1/10.
2 of the last 4 quarters beat the estimate; this quarter's +3.6% surprise compares with a +2.4% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Analyst target reached - limited upside remaining
- Negative news sentiment (-0.67)
- Earnings estimates trending DOWN
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $50.83
- Stop
- $49.03
The stock trades at 26.1× trailing but 19.5× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 93 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
QGEN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $10.50B
- P/E (fwd)
- 19.5
- P/E (ttm)
- 26.1
- 52-week range
- $32.53–$57.82
- Off 52-week high
- 12.1%
- RSI (14)
- 93
- Volume vs avg
- 0.55×
- Score today
- 5.1/10